## ICADE AND PRIMONIAL REIM SIGN AN EXCLUSIVITY AGREEMENT FOR THE ACQUISITION OF ICADE'S STAKE IN ICADE SANTÉ

March 14, 2023




Desirable places to live





An exclusivity agreement signed between Icade, Icade Santé's minority shareholders and Primonial for (i) the acquisition of Icade's stake in Icade Santé (58%) and (ii) the sale of the asset portfolio owned by Icade Healthcare Europe (IHE)




EVALUATION OF SUPPORT AND A SUP

These include confirmation by the AMF that the transaction will not give rise to a buyout offer with squeeze-out for Icade's share capital, pursuant to Article 236-6 of the AMF's general regulations

(3) After adjusting for the 2022 dividend




#### The proposed transaction would enable Icade to realise the value of its investments in Icade Santé ("IS") and Icade Healthcare Europe ("IHE") in three stages (deconsolidation from June 2023)





#### A significantly stronger balance sheet and liquidity to support the new strategy enabling lcade to seize opportunities

#### **Current situation**



• Significant deleveraging and strengthening the BBB+ rating

Benefits of the transaction

- More headroom and agility to anchor a new strategy and seize opportunities
- A streamlined business model: refocusing on Office Investment and Property Development
  - Opportunistic acquisitions and optimised use of our land bank to develop projects in line with a post-Covid office market undergoing significant changes
  - Increased agility for large-scale Property Development projects
  - $_{\odot}$  New strategy to be defined by the end of 2023
- New long-term sources of capital allowing the Healthcare Property Investment Division to further expand
- Current minority shareholders able to sell and/or to strengthen their position
- Icade Santé teams transferred to form a best-in-class team and undisputed leader in the management of the asset class

MARCH 14, 2023

4

### AN ATTRACTIVE TRANSACTION FOR ICADE AND ITS SHAREHOLDERS



# Finexsi reported on its work and conclusions to Icade's Board of Directors on March 10, 2023, confirming the fairness of the terms and conditions of the transaction for Icade and its shareholders<sup>(1)</sup>



A stronger, less leveraged balance sheet

- Incoming cash-flows of up to ~€3.0bn
- Realization of a significant capital gain with €1.2bn
- Strengthened credit profile in line with a BBB+ rating <sup>(2)</sup>
- Significantly improved debt ratios as early as 2023

Greater market appeal

- Crystallising the value of the Healthcare business close to its EPRA NTA
- Highlighting the highly "excessive" discount at which Icade shares are trading (Icade currently trading at a ~48% discount to EPRA NTA)
- Securing and reinforcing the dividend policy: up to ~€710m in special dividends, payable in the two years following the sales (SIIC tax regime)



